Talks Presented by: Elizabeth Smith, PhD, Tatyana Adayev, PhD, Anne Wheeler, PhD
Summarized by: Carme Torrents Fenoy, MD, Parc Tauli Hospital, Barcelona
Summary
This symposium explored the current state of prenatal and newborn screening for Fragile X syndrome (FXS), highlighting the scientific advances that have enabled early detection, as well as the practical challenges of implementing screening and ensuring families can access timely early intervention services.
Three speakers discussed why identifying FXS before or shortly after birth is valuable, how current screening methods work, and what happens after a child receives an early diagnosis. Together, the presentations examined how earlier identification could improve developmental outcomes for children and give scientists an earlier window while also addressing policy, ethical, and healthcare system barriers.
Prenatal and Newborn Screening in Fragile X Syndrome
Dr. Elizabeth Smith explained that Fragile X syndrome can be detected through DNA testing at different stages of life, including before implantation, during pregnancy, at birth through newborn screening, or later in childhood and adulthood. During pregnancy, small fragments of fetal DNA are present in a pregnant person’s blood and can be analyzed through noninvasive prenatal testing (NIPT), which is routinely used to screen for certain chromosomal conditions.
While many insurance plans cover standard NIPT, expanded NIPT — which is required to screen for FXS during pregnancy — is covered less consistently. Although prenatal and newborn screening for FXS is technically feasible, it is not routinely implemented in the United States. FXS is not currently included in the Recommended Uniform Screening Panel (RUSP), despite the potential benefits of earlier diagnosis and intervention.
Dr. Smith also highlighted recent policy changes, including the elimination of the federal advisory committee that previously reviewed newborn screening recommendations, creating additional uncertainty for future implementation.
Bridging Prenatal and Newborn Screening in Fragile X: Lessons from Feasibility Studies
Dr. Tatyana Adayev reviewed more than two decades of experience with prenatal DNA testing and described ongoing efforts to develop protein-based newborn screening methods. She explained that DNA tests identify changes in the FMR1 gene, while protein-based tests measure levels of the Fragile X protein (FMRP), the protein that is reduced or absent in individuals with FXS.
Results from pilot newborn screening studies conducted in 2014 (approximately 2,000 newborns) and 2020 (1,243 newborns) demonstrated that protein-based screening using dried blood spots is technically feasible. Because Fragile X syndrome is relatively rare — affecting an estimated 1 in 7,000 males and 1 in 11,000 females — and participation in these studies was voluntary, no infants with a full mutation were identified, and only one male premutation carrier was detected.
Dr. Adayev emphasized that future newborn screening programs may combine DNA- and protein-based approaches, with decisions guided by accuracy, cost-effectiveness, and the ability to identify affected infants early enough to benefit from emerging therapies. The goal is to have an inclusive screening strategy that reaches every newborn, not only those identified through family history or prenatal carrier screening.
Access to Early Intervention Services for Newborns with FXS
Dr. Anne Wheeler focused on what happens after newborn screening by examining access to Early Intervention (EI) services. Although infants diagnosed with FXS automatically qualify for Part C Early Intervention because they have an established neurodevelopmental condition, many families still experience delays in referrals, enrollment, and access to services.
Eligibility alone does not guarantee timely or individualized support. FXS-related delays begin in the first year of life, so a confirmed diagnosis — not a demonstrated delay — is the timeliest basis for starting early support. Families frequently face challenges such as delayed referrals, confusion about eligibility, limited availability of specialized services, and the burden of coordinating care across multiple providers.
Findings from the Early Check newborn screening program and the Parent and Infant Inter(X)action Intervention (PIXI) study showed that families often experience stress and uncertainty after diagnosis but greatly benefit from genetic counseling, clear information, and early developmental support. The PIXI program demonstrated that remotely delivered, parent-focused intervention is both feasible and highly acceptable, suggesting that structured coaching programs can provide valuable guidance during the critical first years of life.
Why This Matters
This symposium reinforced that newborn screening is only valuable if it leads to timely support for children and families. Earlier diagnosis gives families access to genetic counseling, developmental monitoring, and Early Intervention services during the period when the brain is developing most rapidly.
Although there are currently no disease-modifying treatments for Fragile X syndrome, early intervention is the most beneficial reason for early diagnosis. Developmental therapies introduced in infancy may improve communication, motor skills, and overall developmental outcomes.
Early diagnosis also reduces the uncertainty many families experience before receiving an explanation for their child’s developmental differences. Identification of barriers that keep eligible infants from being served points to navigation and caregiver coaching as ways to close the gap during the critical first years, turning an early diagnosis into earlier, effective intervention.
The research also highlighted that significant gaps remain between identifying a child with FXS and ensuring that appropriate services are delivered. Families often struggle to navigate complex healthcare and intervention systems, and many providers lack Fragile X-specific expertise.
The research emphasizes that newborn screening should be accompanied by coordinated support, condition-specific guidance, and clear communication. For families affected by Fragile X, these findings suggest that early diagnosis has meaningful benefits today, even as researchers continue to work toward future targeted therapies.
Next Steps
Future research will focus on expanding newborn screening studies to much larger and more representative populations while determining the most effective combination of DNA- and protein-based screening methods. Researchers also plan to evaluate the long-term developmental outcomes of children identified through newborn screening and to continue expanding interventions such as the PIXI program through larger clinical studies.
At the policy level, efforts will continue to advocate for broader implementation of Fragile X newborn screening and stronger connections between screening programs and Early Intervention services.
Ultimately, this work aims to create a comprehensive system in which every infant with FXS is identified as early as possible, connected quickly to specialized support, and prepared to benefit from future disease-targeted treatments as they become available.
